{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:09:32Z","timestamp":1787234972499,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Talent Innovation Capability Cultivation Program of the Army Medical Center","award":["ZXZYTSLCO8"],"award-info":[{"award-number":["ZXZYTSLCO8"]}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0721"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0721"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eclinm.2025.103336","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T13:35:26Z","timestamp":1751981726000},"page":"103336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment outcomes for patients with newly diagnosed or relapsed\/refractory TP53-mutated mantle cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"Na","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiegang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-9039","authenticated-orcid":false,"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-1677","authenticated-orcid":false,"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.eclinm.2025.103336_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103336_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1080\/10428194.2024.2338851","article-title":"Management of relapsed\/refractory mantle cell lymphoma","volume":"65","author":"Alzahrani","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.eclinm.2025.103336_bib3","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103336_bib4","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103336_bib5","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103336_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103336_bib8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103336_bib9","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib10","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10441","key":"10.1016\/j.eclinm.2025.103336_bib11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103336_bib12","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2025.103336_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.eclinm.2025.103336_bib15","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103336_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"27","key":"10.1016\/j.eclinm.2025.103336_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103336_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Base Ment Health"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103336_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bimj.201900036","article-title":"Meta-analysis of the difference of medians","volume":"62","author":"McGrath","year":"2019","journal-title":"Biom J"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103336_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/sim.8013","article-title":"One-sample aggregate data meta-analysis of medians","volume":"38","author":"McGrath","year":"2018","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103336_bib22","first-page":"415","article-title":"Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma","volume":"42","author":"Cao","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.eclinm.2025.103336_bib23","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283724","article-title":"Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group","author":"Carras","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2025.103336_bib24","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood-2022-159805","article-title":"A phase II trial of acalabrutinib in combination with PI3K\u03b4 inhibitor umbralisib and the anti-CD20 antibody ublituximab (AU2) in patients with previously untreated mantle cell lymphoma (MCL)","volume":"140","author":"Danilov","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103336_bib25","first-page":"1149","article-title":"Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation","volume":"109","author":"Epstein-Peterson","year":"2024","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103336_bib26","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","article-title":"Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma","volume":"103","author":"Eskelund","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103336_bib27","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70101","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial","volume":"9","author":"Forsgren","year":"2025","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103336_bib29","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gine","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103336_bib30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma a phase 1\/2 trial","volume":"137","author":"Gouill","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103336_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","article-title":"Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/bloodadvances.2023011920","article-title":"MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial","volume":"8","author":"Jerkeman","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103336_bib33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2024-192939","article-title":"Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the nordic lymphoma group NLG-MCL8 (ALTAMIRA) phase II trial","volume":"144","author":"Jerkeman","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103336_bib34","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103336_bib35","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2024-198056","article-title":"Preliminary efficacy and safety of a phase 1\/2 study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed\/refractory and previously untreated mantle cell lymphoma (MAVO)","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.35754\/0234-5730-2019-64-3-256-273","article-title":"Negative impact of the tp53 gene mutations on the efficacy of the therapy of mantle cell lymphoma. Interim results of the MCL-2016 protocol","volume":"64","author":"Koroleva","year":"2019","journal-title":"Gematol Transfusiol"},{"issue":"Suppl 2","key":"10.1016\/j.eclinm.2025.103336_bib37","first-page":"461","article-title":"Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103336_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103336_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103336_bib40","first-page":"13","article-title":"TP53, NOTCH1\/2 and CD36 mutations predict poor outcome in mantle cell lymphoma; molecular analysis of the fil V-RBAC phase 2 trial","volume":"109","author":"Moia","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2025.103336_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102221","article-title":"Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1\/2 trial of the European MCL network (SAKK 36\/13)","volume":"64","author":"Novak","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103336_bib42","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103336_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103336_bib45","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103336_bib46","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2025.103336_bib47","article-title":"Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: updated results and subgroup analysis from the phase 1\/2 BRUIN study with >3 Years follow-up from start of enrollment","volume":"23","author":"Shah","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103336_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428194.2022.2131407","article-title":"Frontline treatment approaches in TP53-aberrant mantle cell lymphoma","volume":"64","author":"Shah","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103336_bib49","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib\u2013rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103336_bib52","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103336_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.20892\/j.issn.2095-3941.2024.0200","article-title":"Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma","volume":"22","author":"Wang","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103336_bib54","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1007\/s00277-025-06379-x","article-title":"Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma","volume":"104","author":"Yang","year":"2025","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103336_bib55","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.21873\/anticanres.16120","article-title":"Bendamustine plus rituximab for mantle cell lymphoma: a Korean, multicenter retrospective analysis","volume":"42","author":"Yi","year":"2022","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103336_bib56","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103336_bib57","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline treatment of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103336_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103336_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103336_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eclinm.2025.103336_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107615","article-title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","volume":"147","author":"Shen","year":"2024","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103336_bib62","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/bjh.17063","article-title":"A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma","volume":"191","author":"Obr","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2025.103336_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.03.002","article-title":"TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present","volume":"146","author":"Kim","year":"2024","journal-title":"Hum Pathol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025002688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:39:37Z","timestamp":1768829977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025002688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":63,"alternative-id":["S2589537025002688"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103336","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes for patients with newly diagnosed or relapsed\/refractory TP53-mutated mantle cell lymphoma: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103336"}}